| Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target LM Walker, SK Phogat, PY Chan-Hui, D Wagner, P Phung, JL Goss, ... Science 326 (5950), 285-289, 2009 | 2110 | 2009 |
| Broad neutralization coverage of HIV by multiple highly potent antibodies LM Walker, M Huber, KJ Doores, E Falkowska, R Pejchal, JP Julien, ... Nature 477 (7365), 466-470, 2011 | 1748 | 2011 |
| Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 JS McLellan, M Pancera, C Carrico, J Gorman, JP Julien, R Khayat, ... Nature 480 (7377), 336-343, 2011 | 1041 | 2011 |
| Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors M Bonsignori, KK Hwang, X Chen, CY Tsao, L Morris, E Gray, DJ Marshall, ... Journal of virology 85 (19), 9998-10009, 2011 | 503 | 2011 |
| The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus GB Karlsson Hedestam, RAM Fouchier, S Phogat, DR Burton, J Sodroski, ... Nature Reviews Microbiology 6 (2), 143-155, 2008 | 501 | 2008 |
| A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals LM Walker, MD Simek, F Priddy, JS Gach, D Wagner, MB Zwick, ... PLoS pathogens 6 (8), e1001028, 2010 | 443 | 2010 |
| Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120 C Huang, M Venturi, S Majeed, MJ Moore, S Phogat, MY Zhang, ... Proceedings of the National Academy of Sciences 101 (9), 2706-2711, 2004 | 359 | 2004 |
| Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals Y Li, K Svehla, MK Louder, D Wycuff, S Phogat, M Tang, SA Migueles, ... Journal of virology 83 (2), 1045-1059, 2009 | 314 | 2009 |
| Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120–CD4–CCR5 complexes M Moulard, SK Phogat, Y Shu, AF Labrijn, X Xiao, JM Binley, MY Zhang, ... Proceedings of the National Academy of Sciences 99 (10), 6913-6918, 2002 | 302 | 2002 |
| Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1 M Pancera, JS McLellan, X Wu, J Zhu, A Changela, SD Schmidt, Y Yang, ... Journal of virology 84 (16), 8098-8110, 2010 | 279 | 2010 |
| Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1 R Pejchal, LM Walker, RL Stanfield, SK Phogat, WC Koff, P Poignard, ... Proceedings of the National Academy of Sciences 107 (25), 11483-11488, 2010 | 259 | 2010 |
| Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition M Vaccari, SN Gordon, S Fourati, L Schifanella, NPM Liyanage, ... Nature medicine 22 (7), 762-770, 2016 | 214 | 2016 |
| Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120–MF59 in adults GE Gray, LG Bekker, F Laher, M Malahleha, M Allen, Z Moodie, ... New England Journal of Medicine 384 (12), 1089-1100, 2021 | 197 | 2021 |
| Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge T Bradley, J Pollara, S Santra, N Vandergrift, S Pittala, C Bailey-Kellogg, ... Nature communications 8 (1), 15711, 2017 | 139 | 2017 |
| Comparative analysis of 10 small molecules binding to carbonic anhydrase II by different investigators using Biacore technology GA Papalia, S Leavitt, MA Bynum, PS Katsamba, R Wilton, H Qiu, ... Analytical biochemistry 359 (1), 94-105, 2006 | 136 | 2006 |
| Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial LG Bekker, Z Moodie, N Grunenberg, F Laher, GD Tomaras, KW Cohen, ... The lancet HIV 5 (7), e366-e378, 2018 | 116 | 2018 |
| Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies J Clegg, E Soldaini, RM McLoughlin, S Rittenhouse, F Bagnoli, S Phogat Frontiers in immunology 12, 705360, 2021 | 103 | 2021 |
| Rational modifications of HIV-1 envelope glycoproteins for immunogen design S Phogat, R Wyatt Current pharmaceutical design 13 (2), 213-227, 2007 | 101 | 2007 |
| Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library MY Zhang, Y Shu, S Phogat, X Xiao, F Cham, P Bouma, A Choudhary, ... Journal of immunological methods 283 (1-2), 17-25, 2003 | 100 | 2003 |
| Vaccinology in the post− COVID-19 era R Rappuoli, E De Gregorio, G Del Giudice, S Phogat, S Pecetta, M Pizza, ... Proceedings of the National Academy of Sciences 118 (3), e2020368118, 2021 | 89 | 2021 |
